UNIQUELY POSTIONED TO DELIVER INNOVATIVE TREATMENTS FOR PATIENTS WITH INFECTIOUS DISEASES

Jefferies 2019 Healthcare Conference

Safe Harbor and Disclaimer

Any statements in this presentation about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statementsabout Nabriva Therapeutics’ plans for further interactions with the FDA; the development of Nabriva Therapeutics’ product candidates, such as thefuture development or commercialization of lefamulin and CONTEPO, the clinical utility of lefamulin for CABP and of CONTEPO for cUTI, plans forand timing of the review of regulatory filings, efforts to bring lefamulin and CONTEPO to market, the market opportunity for and the potential marketacceptance of lefamulin for CABP and CONTEPO for cUTI, the potential benefits under its license agreement with Sinovant Sciences, thedevelopment of lefamulin and CONTEPO for additional indications, the development of additional formulations of lefamulin and CONTEPO, plans topursue research and development of other product candidates, its ability to achieve any of the specified regulatory or performance milestones underits loan agreement with Hercules Capital, the sufficiency of Nabriva Therapeutics’ existing cash resources and other statements containing the words“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,”“continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including:Nabriva Therapeutics’ ability to resolve the matters set forth in the Complete Response Letter it received from the FDA in connection with its NDA forCONTEPO (fosfomycin) for injection; Nabriva Therapeutics’ reliance on third-party manufacturers to manufacture the clinical and commercial supplyof its product candidates and the ability of such third parties to comply with applicable regulatory requirements; the content and timing of decisionsmade by the U.S. Food and Drug Administration and other regulatory authorities, Nabriva Therapeutics’ ability to realize the anticipated benefits,synergies and growth prospects of its acquisition of Zavante Therapeutics, the uncertainties inherent in the initiation and conduct of clinical trials,availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative ofthe results of ongoing or future trials, whether results of ZEUS will be indicative of results for any ongoing or future clinical trials and studies ofCONTEPO, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercialpotential of product candidates including lefamulin for use as a first-line empiric monotherapy for the treatment of CABP and CONTEPO for thetreatment of cUTI, the ability to retain and hire key personnel, the sufficiency of cash resources and need for additional financing and such otherimportant factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the U.S. Securities and ExchangeCommission. In addition, the forward-looking statements included in this presentation represent Nabriva Therapeutics’ views as of the date of thispresentation. Nabriva Therapeutics anticipates that subsequent events and developments will cause its views to change. However, while NabrivaTherapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. Theseforward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of thispresentation.

2

Nabriva in 2019: A Transformative YearExpect to Successfully Launch Two First-in-Class Antibiotics

Lefamulin is the lead molecule of a new class of antibiotics with positive results in two pivotal Phase 3 trials for CABP*

Focused launch preparation currently ongoing expected to lead to successful launch of two, first-in-class antibiotics

* Lefamulin and CONTEPO are investigational drug candidates and have not received regulatory approval for any indication. Information provided in this slide is based on research and development performed to date.

Lefamulin and CONTEPO are highly complementary and are expected to share call points and utilize focused commercial, medical affairs and supply chain infrastructure

CONTEPO is a potential first-in-class hospital based IV antibiotic for cUTI in the U.S. market with a differentiated mechanism of action and activity against MDR organisms*

PDUFA date of August 19, 2019 for lefamulin. CRL for CONTEPO received April 30, 2019 due to issues related to facility inspections and manufacturing deficiencies at one contract manufacturer. The FDA did not request any new clinical data and did not raise any concerns with regard to the safety of CONTEPO.

3

Troubling Trends in Antimicrobial ResistanceCongress and FDA Taking Specific Actions to Encourage Antibiotic Development

4

The rise of Antimicrobial Resistance (AMR) could have devastating effects

Numerous initiatives launched toaddress urgent needs

http://amr.bd.com/assets/pdf/amr-threat-response.pdf

GAIN Act,21st Century Cures Act, LPAD1

President’s Council on Science and Technology (PCAST)2

Reimbursement Reform,REVAMP, DISARM3

Funding Avenues: NIH, BARDA, DTRA, CarbX4

Nabriva: Strongly Positioned to Deliver Innovative TreatmentsInvestments in preparation set us apart from other antibiotic companies

2 molecules of novel classes with new, differentiated mechanisms of action

Highly experienced and talented HQ and field-based team committed to building a best-in-class anti-infective company

Engaging the scientific community and profiling top accounts to identify those with the highest unmet need in anticipation of a faster uptake, while building for the long term

5

Goal: Successful Launches

Lefamulin

Lefamulin and CONTEPO

Nabriva PortfolioHighly Complementary Customer Base And Positioning Creates Significant Potential Synergies(1)

6

Aligned Positioning Message

(1) Symphony Data: Antibiotic Spend in US Hospitals, 2016(2) TDM: Therapeutic Drug Monitoring

First-in-class

Antibiotics

Complete Spectrum of Activity

Generally Well

Tolerated Profiles

Carbapenem & Quinolone

Sparing

CONTEPO

“Right Spectrum, Right from the Start”

Complete Spectrum of Coverage of Main CABP Pathogens

Generally Well Tolerated Profile

New ClassNew Mechanism of Action (MOA)

Convenient for Patients in Hospital, Transition of Care and the Community

Excellent PK-PD Profile

Active Against Common And Problematic Cuti Pathogens, Including MDR Strains

Generally Well Tolerated ProfileNo TDM(2)

Potentially First In Class Injectable In The USNew, Differentiated MOA

No Cross-resistanceSynergy With Other Classes Of Antibiotics

Stable Clinical Profile Despite Decades Of Use

Nabriva’s Strategic Areas of Focus

7

Potentially launch two new classes of antibiotics in 2019

Capture the significant potential opportunity for lefamulin in the community in a financially justifiable way

License lefamulin ex-US in ways that bring in non-dilutive financing and create longer term shareholder value

Assess complementary assets in the anti-infectives space or adjacencies which leverage Nabriva’s commercial infrastructure

Carefully manage financial resources to ensure optimal investments without unnecessary balance sheet risk

Nabriva Leadership TeamSignificant hospital and community based commercial experience

8

Systematic Approach to Pre-Commercial Activities Focused on Medical Education, Identification of Priority Accounts and Patient Access

9

Focus on

Outpatients (Transition of Care)

Market Development ongoing to identify accounts with:

• High macrolide or β-Lactams resistance

• Higher than average: C. difficile rate CABP mortality rate CABP readmission rate Reimbursement penalties for CABP

• Fluoroquinolone restrictions for CABP

• Higher incentive ($) to deflect admissions or to accelerate patients discharge on oral therapy

Lefamulin Hospital Initiated Business Opportunity(1)

~1,600 Accounts represent >80% PatientsCONTEPO Business Opportunity(2)

~900 Accounts represent >80% Patients

Market Development ongoing to identify accounts with:

• High Carbapenem and other resistance

• Higher than average: CRE rate ESBL rate MDR Pseudomonas rate MDR Acinetobacter rate

• Any Carbapenem restriction in place

• Accounts allowing Off-Formulary purchase

Focus on

High Carbapenem Resistance Accounts

(1) Symphony Data: Antibiotic Spend in US Hospitals, 2016(2) Pharma Intelligence Consulting Primary Research Prescribing Physicians, September 2016(3) As of December 31, 2018

Higher Unmet Medical Needs

Issues with CMS KPIs

Infrastructure Alignment

Priority Accounts

>550 Accounts Profiled to Date(3)

LEFAMULIN COMMERCIAL OPPORTUNITY

CABP Patient Admitted to the General Floor

• ≥ 65 years of age• Risk Factors or history of infection caused by resistant organisms (e.g. MRSA)• One or more co-morbid conditions not controlled (e.g. COPD, Kidney Disease,

Diabetes)• Need to change first-line therapy• Minimize exposure to days in hospital• Discharge on oral monotherapy

The Right Spectrum, Right from the StartLefamulin Target Patient Population

11

CABP Patient Treated in the ED

• ≥60 years of age• Risk Factors or history of infection caused by resistant organisms (e.g.

MRSA)• Controlled co-morbid condition (e.g. COPD, Kidney Disease)• Don’t want to admit patient to ward• Minimize exposure of total days on ABX• Release on oral monotherapy

Pneumonia: A Leading Cause of Morbidity, Mortality and Cost

#3 Cause of hospital readmission2

5-6MMApproximately

CABP Cases Annually

1: el Bcheraoui C, Mokdad AH, Dwyer-Lindgren L, et al. Trends and Patterns of Differences in Infectious Disease Mortality Among US Counties, 1980-2014. JAMA. 2018;319(12):1248–1260. doi:10.1001/jama.2018.20892: Fingar K, Washington R. Trends in hospital readmissions for four high-volume conditions, 2009-2013: Statistical Brief #196. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Healthcare Research and Quality; November 2015. http//www.hcup-us.ahrq.gov/reports/statbriefs/sb196-Readmissions-Trends-High-Volume-Conditions.pdf. Accessed February 23, 2016. 3: HCUP Fast Stats - Most Common Diagnoses for Inpatient Stays – 2015 https://www.hcup-us.ahrq.gov/faststats/NationalDiagnosesServlet4: 2017 CHARTBOOK STATIC ANALYSES - Trends in mortality rates following admission for acute myocardial infarction, chronic obstructive pulmonary disease, heart failure, pneumonia, and acute ischemic stroke. Prepared for CMS by Yale New Haven Health Services Corporation - Center for Outcomes Research and Evaluation (YNHHSC/CORE) September 2017 5: Joya-Montosa Critical Care 2015 19(Suppl 1):P19. 6: AlOtair Journal of Taibah University Medical Sciences Volume 10, Issue 3, Sept. 2015, Pages 293-299. 7: File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130–41.

#5 Cause of total hospitalizations3

#1 Cause of infectious death1

Mortality rates

~$17BDirect hospitalization costs of CAP7

~15%in hospital4

~25 – 30%in ICU5,6

12

In-PatientsPrioritized Accounts

Significant Opportunities in the Treatment of CABPTargeted Commercial Strategy to Accelerate Adoption and Market Uptake

Favorable reimbursement environment (not on DRG) in the ED

‘Observation Status’ allows hospital to charge at ASP+6%

Collateral damage and safety issues with fluoroquinolones

Low risk of C. difficile infection

Prevent admission/readmission

Limited oral monotherapy options for existing treatments

Opportunities for lefamulin

Hospital In Patient~ 3.8MM Patients

Patients numbers approximately six years after launch, if approved & continue to grow until LOE, following the CABP epidemiology growth**~3.0MM Hospital Initiated Outpatients and ~0.9MM of ED Outpatients. See appendix for references.CABP Competitive Analysis, Nabriva Sponsored Market Research, Ipsos Feb 2018

OutpatientsTransition of Care

Hospital Discharge~ 2.4MM Patients

ED Treatments & Discharge~ 0.9MM Patients

13

FDA & EMA has Issued Numerous Safety Communications on Fluoroquinolones

FDA web site: Fluoroquinolone antimicrobial drugs information. EMA website: https://www.ema.europa.eu/en/news/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review

2008 2011 2013 2015 2016 2018

July 2008 FDATendinitis and tendon

rupture; “consider risk/benefit in individuals”

Feb 2011 FDA Worsening symptoms

in patients with myasthenia gravis

Aug 2013 FDARisk of peripheral

neuropathy

Nov 2015 FDA Advisory Committee meeting

July 2018 FDA: Distinction between warning for mental health and CNS effects; include

risk of coma with hypoglycemia

July 2016 FDA“Serious side effects associated with FQs generally

outweighs the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated UTI”

Reserved for those without alternative treatment options. Adverse effects include tendons, muscles,

joints, nerves, CNS

May 2018 EMA: Recommendation to restrict the use of fluoroquinolone following a review of disabling and potentially long-lasting side

effects

Dec 2018 FDA: “fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the main artery of the body, called the aorta”

Oct 2018 EMA: New warning regarding risk of aortic aneurysm and dissection associated

with fluoroquinolones for systemic and inhalation use

14

• Central Nervous System (CNS) effects• Aneurysm• Exacerbation of Myasthenia Gravis• Hepatotoxicity• Photosensitivity/Phototoxicity• Hypersensitivity• Peripheral Neuropathy• Retinal Detachment• QT prolongation/ Torsades de

Pointes/Arrhythmias• Blood Glucose Disturbances• C. difficile-associated Diarrhea• Tendinitis/Tendon Rupture

Safety concerns have led to decreased prescriptions

Fluoroquinolone Associated Serious Safety Concerns Fluoroquinolones and Risk for Aortic Aneurysm and Rupture or Dissection

Opportunity for lefamulin to fill void

15

Image source:http://saithsjwmeq.wordpress.com/2014/09/19/female-anatomy-whole-body-learning-human-anatomy-guy-4th-edition-download/ Antimicrobial Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. FDA Briefing Document. 2015. at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm467380.htm.) Accessed 20 Mar 2016.

Aneurysmoccurs in

≈1 in 300for those athighest risk

• FDA warns that the use of systemic fluoroquinolone antibiotics has been associated with the rupture or dissection of aortic aneurysms. Health care professionals should avoid prescribing fluoroquinolone antibiotics to patients who have an aortic aneurysm or are at risk for an aortic aneurysm, such as patients with peripheral atherosclerotic vascular diseases, hypertension, certain genetic conditions such as Marfansyndrome and Ehlers-Danlos syndrome, and elderly patients. Prescribe fluoroquinolones to these patients only when no other treatment options are available.

• The background risk of aortic aneurysm depends on the population and can vary with estimates from 9 aortic aneurysm events per 100,000 people per year in the general population to 300 aortic aneurysm events per 100,000 people per year in individuals at highest risk.

16

There is a Clear Trend Toward Reducing Fluoroquinolones Useboth in the Hospital and in the Community

Source: IQVIA, NSP Audit Extended Units, All-Outlet (Hospital & Retail)Extended units are the number of tablets, capsules, milliliters, ounces, etc. of a product shipped in each unit. This number is calculated by multiplying the number of units by the product size.

Increased Fluoroquinolone restrictions, including specific limitations for CABP, are leading to a reduced use

FQ Usage in the Hospital & Retail Combined has Declined in Recent Years

Still, Fluoroquinolones remain the most commonly prescribed antibiotics in the hospital

1,500,000,000

2,000,000,000

2,500,000,000

3,000,000,000

3,500,000,000

4,000,000,000

4,500,000,000

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Exte

nded

Uni

ts

Fluoroquinolones Volume Trends

Substantial Lefamulin Commercial OpportunityLefamulin’s innovative profile is well suited for 3 distinct and significant opportunities in the treatment of CABP

Market Share Scenario(1)CTotal Estimated Addressable Population

Transition of Care

~3.3MMA**ED Discharged Out-Patient

IV to Oral (or Oral): ~100% ~0.9 MM Patients

Discharged on OralC : ~80% ~2.4 MM PatientsIn-Hospital initiated Discharged Out-Patient

1st Empiric TherapyC: ~90% Hospital In Patient

~3.0MMA 2nd-3rd Line TherapyC: ~30%

~2.7 MM Patients

~0.9 MM Patients

Community CABP

~2.3MMB Oral Treatment ~100% ~2.3MM Patients

~5%

~10%

135K Pts

90K Pts

~10% 230K Pts

~15% 150K Pts

~15% 300K Pts

Potential Lefamulin Pts ~1.0MM(1) Market share scenario approximately six years after launch, if approved. In the scenario, patients numbers are ten years after launch. Sales continue to grow from peak market share

after launch until LOE, following the CABP epidemiology growth**~3.0MM Hospital Initiated Outpatients and ~0.9MM of ED Outpatients. See appendix for references.(2) Lefamulin in an investigational drug candidate and has not received regulatory approval for any indication. Information provided in this slide is based on research and development

performed to date.A: Healthcare Cost and Utilization Project (HCUP) 2013, Age 18+ (projected to 2029)B: Community Data (CDC 2009-2010), Age 18+ (projected to 2029)C: Company Sponsored Market Research, Medical Marketing Economics, July 2016, (N=122) 17

CONTEPO COMMERCIAL OPPORTUNITY

The Right Spectrum, Right from the StartCONTEPO Target Patient Population

19

Resistance is a Growing Concern in the Treatment ofGram Negative Infections

(1) DeRyke et al, Poster # 332, ASM Microbe 2016(2) IQVIA NSP Sales Database, 2005-2015(3) Schneider et al, Boston Health Economics, at The Society for Healthcare Epidemiology of America 2017; Future projections based on Nabriva’s estimates on current trends(4) Patolia et al, Ther Adv Infectious Dis 2018, Vol. 5(1) 11–18(5) Nelson et al, Infect Control Hosp Epidemiol 2017;38:848–856

Carbapenem use has more than doubled in the US between 2005 and 2015(2)

ESBL resistance rates increased steadily from 2008 through 2015 in ambulatory, admission, and hospital settings in the U.S. with E coli accounting for 71% of all ESBLs(1)

… and now resistance to carbapenems is the latest threat

CRE (Carbapenem Resistant Enterobacteriaceae) trend in the US poses a real concern since, for cUTI, Carbapenems often used as antibiotic of last resort and it’s expected to grow in future (3)

When infections are resistant to carbapenems, other β-lactams and other antibiotic classes (i.e. MDR), the mortality can be very high (>30%) and can almost double as compared to infections with non-MDR pathogens(4,5)

…has led to an increased reliance on carbapenem therapy…Increased ESBL ….

20

Time to Initiation of Appropriate Therapy: Key to Clinical SuccessAppropriate initial antibiotic therapy predicts positive outcomes

aP < 0.05.1. Micek et al. BMC Infect Dis. 2012;12:56. 2. Joo et al. Infection. 2011;39:309-18. 3. Kumar et al. Chest. 2009;136:1237-48. 4. Dupont et al. Intensive Care Med. 2001;27:355-62. 5. Ibrahim et al. Chest. 2000;118:146-55. 6. Ruiz et al. Am J Respir CritCare Med. 2000;162:119-25. 7. Kollef et al. Chest. 1999;115:462-74. 8. Rello et al. Am J Respir Crit Care Med. 1997;156:196-200. 9. Luna et al. Chest. 1997;111:676-85.

Inappropriate initial antimicrobial therapy is defined as an antimicrobial regimen that lacks in vitro activity against the isolated organism(s) responsible for the infection.1

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Luna (1997) Rello (1997) Kollef (1999) Ruiz (2000) Ibrahim(2000)

Dupont (2001) Kumar (2009) Joo (2011) Micek (2012)

Mor

talit

y R

ate

Appropriate initial therapy Inappropriate initial therapy

21

In-PatientsPrioritized Accounts

CONTEPO: A Potential Alternative to Pip/Taz and CarbapenemsAttractive carbapenem-sparing monotherapy for cUTI patients at risk for MDR organisms(2)

22

Large unmet need in the United States in treating patients with MDR gram-negative infections, with mortality increasing

Increased resistance to carbapenems and other beta-lactams

Increased resistance and safety concerns with fluoroquinolones

Appropriate coverage of MDR organisms in empiric therapy for seriously ill patients is problematic

Key Issues & Opportunity

~ 3.0MM(1) Patientstreated for

Suspected or Confirmed MDR

(1) 2017 Projection, Decision Resources, Hospital Treated Gram Negative Infections, Disease Landscape and Forecast, Dec 2015(2) Pharma Intelligence Consulting Primary Research Prescribing Physicians, September 2016

Current Treatment in the Hospital(2)

Substantial CONTEPO Commercial Potential Modest market share drives significant potential sales

CONTEPO Market Share Scenario(2)

~8%

~12%

112K Pts

72K Pts

Potential CONTEPO Patients at peak >175K And >700K Patients Days of Therapy

Total Estimated Addressable Population (1-2)

Suspected(2) ~ 40% UTI

~3.3MM(1)

Confirmed(2): ~20%

~1.3 MM Patients

~0.6 MM Patients

Treated with MDR coverage: Share Patients

3

5.5

DOT

336K

396K

Patient Days

~2% 8K Pts

Other Gram Negative

Not Promoted (3)

~1.8MM(1)

Suspected or Confirmed MDR (2): ~20% ~0.4 MM Patients 5.5 44K

(1) 2026 Projection, Decision Resources, Hospital Treated Gram Negative Infections, Disease Landscape and Forecast, Dec 2018(2) Pharma Intelligence Consulting Primary Research Prescribing Physicians, September 2016 : Anticipated Usage adjusted downward by >50% (3) CONTEPO studies in cUTI in US only, usage for other MDR indications is for modelling purposes only based on approved indications outside the US

23

FOCUSING ON NABRIVA’S FUTURE

Lefamulin Future Opportunity: CommunityOral only formulation makes the community a significant potential opportunity

25

Hospital Discharge

Office BasedHospital In Patient

OutpatientsTransition of Care

ED Treatments & Discharge

In-PatientsPrioritized Accounts

CommunityFuture/Partnering Opportunity

For lefamulin

Lefamulin and CONTEPOInitial Focus in the Hospital

LefamulinFuture Opportunity

Nabriva in 2019: A Transformative YearKey Anticipated Milestones

26

1H2019

Regulatory filing in EMA for lefamulin

for CABP

August2019

PDUFA date for lefamulin

Ongoing Business Development Activities

April2019

PDUFA date for CONTEPO

2H2019

Potential launch for lefamulin

Financial Highlights

27

$91MM Cash, cash equivalents and short term

investments as of March 31, 2019

Cash resources after initial draw of debt expected to

fund operations into Q2 ‘20

72.6MMordinary shares

as of April 30, 2019

$75MM Debt Facilityestablished in December

2018

Nabriva in 2019: A Transformative YearExpect to Successfully Launch Two First-in-Class Antibiotics

Lefamulin is the lead molecule of a new class of antibiotics with positive results in two pivotal Phase 3 trials for CABP*

Focused launch preparation currently ongoing expected to lead to successful launch of two, first-in-class antibiotics

* Lefamulin and CONTEPO are investigational drug candidates and have not received regulatory approval for any indication. Information provided in this slide is based on research and development performed to date.

Lefamulin and CONTEPO are highly complementary and are expected to share call points and utilize focused commercial, medical affairs and supply chain infrastructure

CONTEPO is a potential first-in-class hospital based IV antibiotic for cUTI in the U.S. market with a differentiated mechanism of action and activity against MDR organisms*

PDUFA date of August 19, 2019 for lefamulin. CRL for CONTEPO received April 30, 2019 due to issues related to facility inspections and manufacturing deficiencies at one contract manufacturer. The FDA did not request any new clinical data and did not raise any concerns with regard to the safety of CONTEPO.

28

Questions?